Wells Fargo Cuts PT on Globus Medical (GMED) Despite Q1 Sales and EPS Beat

In its fiscal results for fiscal Q1 2026, Globus Medical, Inc. (NYSE:GMED) reported worldwide nett income of $759.9 million, reflecting an summation of 27.0%, oregon an summation of 25.5% connected a changeless currency basis. Management further reported that basal business, excluding Nevro, nett income were $677.2 million, up 13.2%, oregon an summation of 11.2% connected a changeless currency basis. The institution headed disconnected a beardown commencement to the year, with grounds Q1 net and integrated gross maturation driven by stock gains and procedural measurement spot successful halfway spine. Keith Pfeil, President and Chief Executive Officer, besides stated that Enabling Technologies delivered against its pipeline and continued to grow the company’s lawsuit base.

Globus Medical, Inc. (NYSE:GMED) is simply a aesculapian instrumentality institution progressive successful the improvement and commercialization of healthcare solutions. The institution classifies its products into Innovative Fusion and Disruptive Technology, and operates done the United States and International geographical segments.

While we admit the imaginable of GMED arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey connected Google News.